A Multicenter Phase II Study of Modified FOLFIRINOX for First-Line Treatment for Advanced Urachal Cancer (ULTIMA; KCSG GU20-03)
In this preliminary analysis of the ULTIMA trial, Modified FOLFIRINOX demonstrated a promising ORR and PFS in patients with advanced urachal cancer. Completing the full study is essential to confirm the potential role of this regimen in the management of advanced urachal cancer.
Authors
- Seong Hoon Shin
- Inkeun Park
- Sang Joon Shin (ORCID: https://orcid.org/0000-0001-5350-7241)
- Jae‐Lyun Lee (ORCID: https://orcid.org/0000-0002-9420-7162)
- Kwonoh Park (ORCID: https://orcid.org/0000-0002-7404-1257)
- Jung Hoon Kim (ORCID: https://orcid.org/0000-0002-0947-876X)
- Hyo Jin Lee (ORCID: https://orcid.org/0000-0001-8378-3001)
- Shinkyo Yoon
Institutions
- Ulsan College (KR)
- Yonsei University (KR)
- Kosin University Gospel Hospital (KR)
- Asan Medical Center (KR)
- University of Ulsan (KR)
- Hanyang University Seoul Hospital (KR)
- Chungnam National University Hospital (KR)
- Pusan National University Yangsan Hospital (KR)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2025-02-13
- DOI
- https://doi.org/10.4143/crt.2024.1231
- Citations
- 3
- Primary Topic
- Urinary and Genital Oncology Studies
- Type
- article
- Field-Weighted Citation Impact
- 6.02
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Merck KGaA
- Seagen
- LG Chem
- Genentech